VectorialDATA

LLY — Eli Lilly and Company

हेल्थकेयरउत्तर अमेरिकासंयुक्त राज्य अमेरिकाब्लॉकचेन प्रमाणित

चुनते समय कीमत (23 जुल॰ 2026)

$1146.62

लक्ष्य: $1236.00 (+7.8%)

P/E Ratio

40.7

P/E Forward

25.6

लाभांश

0.54%

मार्केट कैप

$1057.5B

EPS

$28.14

सर्वसम्मति

खरीद

यह कंपनी क्या करती है

Eli Lilly (NYSE: LLY) duniya ki sabse badi aur sabse purani dawa companiyon mein se ek hai, jo 1876 mein Indianapolis mein sthapit hui. Aaj iska growth (badhotri) ka engine ek hi dawa parivaar hai —jinhe incretins ya GLP-1 kehte hain— jo sharir ke ek hormone ki nakal karke bhookh kam karti hain aur khoon mein sugar control karti hain.

Star products:

  • Mounjaro (tirzepatide, injection) — type 2 diabetes ke liye. Q1 2026 mein $8.66 अरब (+125%) kamaye, aur pehli baar US ke bahar US ke andar se zyada bikti hai.
  • Zepbound (wahi tirzepatide) — motape aur sleep apnea ke liye approved. Tikoni mein US bikri $4.16 अरब (+80%).
  • Foundayo (orforglipron) — nayi jewel: wazan ghatane ke liye GLP-1 type ki pehli goli, jise FDA ne 1 April 2026 ko approve kiya. Ab tak yeh dawaiyan sirf injection mein milti thin; ek goli banana aur lena bahut aasan hai (khane ya paani ki koi rok-tok nahi), aur yeh karodon naye mareezon ke liye darwaza kholti hai.
  • Kisunla (donanemab) — shuruaati Alzheimer ke liye: dimaag ki plaques saaf karti hai. Abhi bas chalne lagi hai.
  • Verzenio (breast cancer), Taltz (psoriasis), Jardiance (diabetes/dil, Boehringer ke saath), aur naye launches ki ek katar (eczema ke liye Ebglyss, Omvoh, Jaypirca).

Abhi kyun tezi hai: motapa ab tak khula sabse bada dawa bazaar hai —karodon log—, aur Lilly sabse taakatwar dawa ke saath aayi aur ab pehli goli ke saath bhi. GLP-1 ke duniya bazaar ka karib 60% ispar hai.

Leadership: CEO David A. Ricks (January 2017 se, board ke chairman bhi). Headquarters Indianapolis, Indiana mein. ~50,000 karmchari. 2026 mein company 150 saal poore karti hai.

हमें क्यों पसंद है

LLY ko $1,146.62 par kharidna modern medicine ki sabse badi lehar ke bejod leader ko kharidna hai, ek munafa-vasooli mein jiske peeche koi buri khabar nahi. Thos wajahein:

  • Aisi growth (badhotri) jo iske size ki lagbhag koi company nahi kar paati. Q1 2026 (30 April ko report) mein $19.8 अरब, +56% kamaye, aur adjusted per share earnings (EPS) +156% badha. Aur saal ka target badhakar $82-85 अरब revenue kar diya —2025 se 40% se zyada oopar—.
  • Bazaar par dabdaba. Iske tirzepatide ke do version (Mounjaro + Zepbound) ne ek hi tikoni mein $12.8 अरब kamaye (~$51 अरब saal ke). Lilly ke paas global GLP-1 bazaar ka ~60% hai.
  • Goli sab kuch badal deti hai. Foundayo, wazan ghatane ke liye pehli GLP-1 goli, 1 April ko approve hui. Ek goli banana sasta hai aur injection se kahin zyada logon tak pahunchti hai: yeh pehle se hi bahut bade bazaar ka agla step hai.
  • Iska pratidvandi abhi ladkhadaya. Novo Nordisk ki pratidvandi dawa (CagriSema) Zepbound ke saamne aamne-saamne muqable mein haar gayi (20% vs 24% wazan ghatana), aur Novo anuman lagati hai ki 2026 mein uski motape ki bikri ghategi jabki Lilly apna target badha rahi hai.
  • Yeh dikhne se sasti hai. +40% badhne wali company ke liye ~26 guna expected earnings par trade karti hai —salon mein iski sabse waajib valuations mein se ek—, aur humne apne all-time high $1,249 se ~8% neeche khareeda, jo 7 July ko chhua tha. 'Buy' rating, average target ~$1,236 (UBS $1,425 dekhta hai). 5 August ko report karegi: ek nazdeeki catalyst.

मुख्य जोखिम

Risks:

  • Bahut oonchi valuation aur ummeedein — #1: ~$1.06 ट्रिलियन market value aur ~41 guna historical earnings par, keemat pehle se hi behadd saaf execution maan chuki hai; average target (~$1,236) sirf ~8% oopar hai, aur 5 August ki report mein ek bhi ladkhadahat ko bahut sazaa milti hai.
  • Competition: Novo Nordisk bazaar ke liye lad rahi hai aur ek price war shuru kar chuki hai —Lilly ki asli keematein tikoni mein ~13% giri—; aage Amgen aur Viking apni dawaiyon ke saath aati hain (pehle launches ~2027).
  • Sarkar ka price dabaav: US kam keematein majboor kar rahi hai (ek deal Mounjaro/Zepbound ko Medicare ke liye ~$245/mahina par le aati hai), aur kuch dawaiyan Medicare ki anivaarya price negotiation mein aa chuki hain.
  • Patent samaapti: halaanki tirzepatide ~2036 tak surakshit hai, doosri dawaiyan (Trulicity, Jardiance, Verzenio) is dashak mein suraksha khoti hain aur us revenue ko badalna padta hai —isiliye Lilly lagatar companiyan khareedti rehti hai (abhi AtaiBeckley ke liye $3.8 अरब tak diye)—.
  • Ek business, ek daav: value ka bada hissa tirzepatide par nirbhar hai; us parivaar mein koi safety, manufacturing ya regulatory samasya bahut zor se maaregi.

यह शैक्षिक और सूचनात्मक सामग्री है, वित्तीय सलाह नहीं। निवेश निर्णय लेने से पहले हमेशा एक योग्य वित्तीय सलाहकार से परामर्श लें।

Vectorial Data ने LLY को 23 जुल॰ 2026 को $1146.62 पर चुना।

पूर्ण रिसर्च

Eli Lilly (LLY) — Poora Research

Price: $1,146.62 | P/E TTM: ~41x | P/E fwd: ~26x | Div Yield: ~0.5% | Market Cap: ~$1.06 ट्रिलियन USD


Eli Lilly kya hai?

Duniya ki sabse badi aur sabse purani dawa companiyon mein se ek, 1876 mein Indianapolis mein Colonel Eli Lilly dwara sthapit. November 2025 mein yeh itihaas ki pehli healthcare company bani jiski keemat ek ट्रिलियन dollar hui. Iska engine aaj GLP-1 / incretins dawaiyon ka parivaar hai: yeh ek prakritik hormone ki nakal karti hain jo bhookh kam karta hai aur khoon mein sugar control karta hai. CEO David A. Ricks (January 2017 se). ~50,000 karmchari. 2026 mein 150 saal poore.

Products (Q1 2026)

ProductKis liyeBikri Q1 2026
Mounjaro (tirzepatide)Type 2 diabetes$8.66 अरब (+125%)
Zepbound (tirzepatide)Motapa / sleep apnea$4.16 अरब US (+80%)
Foundayo (orforglipron)Wazan ghatane ki pehli GLP-1 goliAbhi launch hui (1 April 2026 ko approved)
Kisunla (donanemab)Shuruaati Alzheimer$124 करोड़ (ramp)
VerzenioHR+ breast cancer~$5.5 अरब/saal
Jardiance, Taltz, Ebglyss…Diabetes/dil, psoriasis, eczemaArbon dollar ki franchises

Mounjaro + Zepbound = ek hi tikoni mein $12.8 अरब (~$51 अरब annualized). Lilly ke paas GLP-1 ke duniya bazaar ka ~60% hai.

Pichhli tikoni (Q1 2026, 30 April 2026 ko report)

MetricQ1 2026
Revenue$19.8 अरब (+56%) (volume +65%, price −13%)
Adjusted EPS (non-GAAP)$8.55 (+156%)
GAAP EPS$8.26 (+170%)

2026 guidance badhaya: revenue $82-85 अरब (pehle $80-83), adjusted EPS $35.50-37.00. Iska matlab 2025 se ~+40% growth. Agli report: 5 August 2026 (consensus ~$20.5 अरब / EPS $7.74).

Kahani: GLP-1 lehar

  • Motapa ab tak khula sabse bada dawa bazaar hai: duniya mein karodon sambhaavit mareez.
  • Foundayo (goli) mukhya catalyst hai: 1 April 2026 ko approved, yeh wazan ghatane ki pehli GLP-1 goli hai; studies mein ~12% tak wazan ghatana, khane ya paani ki koi rok-tok ke bina. Ek goli banana sasta hai aur injection se kahin zyada logon tak pahunchti hai.
  • Pratidvandi ladkhadaya: Novo Nordisk ki CagriSema Zepbound ke saamne aamne-saamne muqable mein haar gayi (20% vs 24% wazan ghatana); Novo anuman lagati hai ki 2026 mein uski motape ki bikri ghategi.
  • Aastin ka agla ikka: retatrutide, antim charan mein, ne May 2026 mein aisa kuch haasil kiya jo pehle kabhi nahi dekha gaya — ek bade study (TRIUMPH-1) mein 30%+ average wazan ghatana (~38 kilo), kisi bhi dawa se sabse zyada; 23 July ko isne dil ki safety ke shak door kar diye.

Dividend (chhota par badhta)

  • $1.73 per share har tikoni = $6.92 saalana = $1,146.62 par ~0.5%. Yeh kam isliye hai kyunki stock upar bhaag gaya, isliye nahi ki payment kamzor hai.
  • 12 saal lagatar badhaya (aakhri badhotri +15%).

Anchor Fact

21 November 2025 ko, Eli Lilly itihaas ki pehli healthcare company bani jiski keemat ek ट्रिलियन dollar hui. Iske wazan ghatane wali dawaiyon ki ek hi tikoni ($12.8 अरब) poori-poori dawa companiyon se zyada kamaati hai — aur iski agli dawa, retatrutide, ne abhi ek bade study mein 30% average wazan ghatana haasil kiya, jo pehle kabhi nahi dekha gaya.

Top 5 Risks

  • Valuation / ummeedein — ~41x historical earnings, ~$1.06 ट्रिलियन value; average target (~$1,236) sirf ~8% oopar; 5 August ki report ek kathin pareeksha hai
  • Competition — Novo Nordisk (price war: asli keematon mein −13%), aur Amgen/Viking ~2027 mein aa rahe hain
  • Sarkar ka price dabaav — MFN deal (~$245/mahina Medicare), Medicare ki anivaarya negotiation
  • Patents — Trulicity (~2027), Jardiance (~2028), Verzenio (~2029) is dashak mein ghisti hain; revenue badalne ke liye lagatar khareed (AtaiBeckley, $3.8 अरब tak, Jul 2026)
  • Tirzepatide par kendrit — us parivaar mein koi safety/manufacturing/regulatory samasya bahut zor se maaregi

Analysts ka consensus

  • Rating: Buy / Overweight (~38 analysts)
  • Average target: ~$1,236 (~+8% $1,146.62 se); S&P ~$1,270
  • Haal ki badhotri (Jul 2026): UBS $1,425, JPMorgan $1,400, Morgan Stanley $1,347

Ek line mein thesis

Modern medicine ki sabse badi lehar —wazan ghatane wali dawaiyan— ka bejod leader, bazaar ki pehli goli ke saath, ~60% hissa aur +40% growth, apne all-time high se ~8% neeche khareeda.

Research date: 23 Jul 2026 | Next review: Jan 2027

Yeh financial salah nahi hai.

हेल्थकेयर सेक्टर के अन्य picks

हेल्थकेयर की सभी देखें →

संयुक्त राज्य अमेरिका के अन्य picks

संयुक्त राज्य अमेरिका की सभी देखें →
रिसर्च की तारीख: 23 जुल॰ 2026अपडेट किया गया: 23 जुल॰ 2026अगली समीक्षा: 23 जन॰ 2027

यह वित्तीय सलाह नहीं है। निवेश करने से पहले किसी प्रमाणित वित्तीय सलाहकार से परामर्श लें।

लेखक चर्चित प्रतिभूतियों में पोजीशन रख सकता है।

पिछला प्रदर्शन भविष्य के परिणामों की गारंटी नहीं देता।

SEBI-पंजीकृत निवेश सलाहकार भारत में व्यक्तिगत सलाह के लिए उपयुक्त पेशेवर हैं। यह सेवा SEBI-विनियमित सलाहकार सेवाएं प्रदान नहीं करती।